Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes

• Status: Completed
• Trial end date: 2006-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to learn more about how muraglitazar lowers blood sugar in people with type 2 diabetes. The safety of this treatment will also be studied.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Collaborator: Merck Sharp & Dohme Corp.
• Treatments: Glycine

Criteria

Inclusion Criteria:

• Type 2 diabetes;

• Serum triglyceride concentration < or = 600 mg/dL;

• Body mass index < or = 37 kg/m2

Exclusion Criteria:

• Type 1 diabetes;

• History of myocardial infarction (MI), coronary angioplasty, bypass graft(s), valvular disease, unstable angina pectoris, transient ischemic attack (TIA), or cerebrovascular accident (CVA) within 6 months;

• Congestive heart failure (NYHA Class III and IV);

• Uncontrolled hypertension;

• Women of Child Bearing Potential

• History of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease, or endocrine disease